Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: PR Newswire
Issued on behalf of Avaí Bio, Inc.VANCOUVER, BC, March 24, 2026 /PRNewswire/ -- Equity-Insider.com — A protein called a-Klotho circulating in the bloodstream protects the brain, heart, kidneys, and the immune system. Peer-reviewed research has linked higher Klotho levels to reduced risk of Alzheimer's, cardiovascular disease, and certain cancers. Mayo Clinic research connects declining Klotho to arterial stiffness and vascular calcification.The challenge is that the body cuts production of this protein by approximately 50% after the age of 40. The molecule that guards against the deadliest age-related diseases starts to decline just as the risk for these conditions starts to rises. Market projections highlight the scale of the issue: Alzheimer's alone is projected to reach $32.8 billion by 2033, cardiovascular disease remains the leading global cause of death, and kidney disease affects 850 million people worldwide.The global cell therapy market has surpassed $8.2 billion in 2026. The
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune (ALT) is now covered by Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.MarketBeat
- Altimmune (ALT) had its price target raised by HC Wainwright from $12.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat [Yahoo! Finance]Yahoo! Finance
- Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up [Yahoo! Finance]Yahoo! Finance
- Altimmune (ALT) had its price target lowered by B. Riley Financial, Inc. from $18.00 to $13.00. They now have a "buy" rating on the stock.MarketBeat
ALT
Earnings
- 3/5/26 - Miss
ALT
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/17/26 - Form ARS
- 3/17/26 - Form DEF
- ALT's page on the SEC website